Intellia Therapeutics Inc (NASDAQ:NTLA) major shareholder Institutes For Biomed Novartis sold 1,523,000 shares of the business’s stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $18.30, for a total value of $27,870,900.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Intellia Therapeutics Inc (NASDAQ:NTLA) opened at $18.37 on Friday. Intellia Therapeutics Inc has a one year low of $10.83 and a one year high of $33.34.

Intellia Therapeutics (NASDAQ:NTLA) last announced its earnings results on Tuesday, October 31st. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.50) by $0.06. Intellia Therapeutics had a negative return on equity of 28.01% and a negative net margin of 215.92%. The business had revenue of $7.30 million for the quarter, compared to analyst estimates of $5.83 million. During the same quarter last year, the firm earned ($0.22) EPS. Intellia Therapeutics’s revenue for the quarter was up 49.0% compared to the same quarter last year. equities analysts forecast that Intellia Therapeutics Inc will post -1.68 EPS for the current fiscal year.

Several equities research analysts recently commented on the company. BidaskClub cut Intellia Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday. Oppenheimer reissued a “hold” rating on shares of Intellia Therapeutics in a research note on Tuesday. ValuEngine cut Intellia Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, November 15th. Barclays reiterated a “buy” rating on shares of Intellia Therapeutics in a report on Sunday, November 5th. Finally, Credit Suisse Group upped their target price on Intellia Therapeutics from $24.00 to $28.00 and gave the company an “outperform” rating in a research note on Friday, November 3rd. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $30.17.

Hedge funds have recently bought and sold shares of the business. SG Americas Securities LLC bought a new position in shares of Intellia Therapeutics during the 2nd quarter worth approximately $101,000. Bank of Montreal Can boosted its stake in shares of Intellia Therapeutics by 1,031.7% during the 2nd quarter. Bank of Montreal Can now owns 7,922 shares of the company’s stock worth $127,000 after acquiring an additional 7,222 shares during the period. Nationwide Fund Advisors boosted its stake in shares of Intellia Therapeutics by 117.7% during the 2nd quarter. Nationwide Fund Advisors now owns 8,048 shares of the company’s stock worth $129,000 after acquiring an additional 4,351 shares during the period. Nisa Investment Advisors LLC acquired a new stake in Intellia Therapeutics during the 2nd quarter worth approximately $134,000. Finally, State of Wisconsin Investment Board acquired a new stake in Intellia Therapeutics during the 2nd quarter worth approximately $160,000. Hedge funds and other institutional investors own 49.55% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was first posted by Watch List News and is owned by of Watch List News. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.watchlistnews.com/institutes-for-biomed-novartis-sells-1523000-shares-of-intellia-therapeutics-inc-ntla-stock/1767110.html.

About Intellia Therapeutics

Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.